Treatment of patients with progression of primary cerebral ependymomas in adults
https://doi.org/10.33667/2078-5631-2023-17-42-45
Abstract
The aim of this work is to evaluate the results of treatment of patients with progression of primary cerebral ependyma in adults. The study included 10 patients who have been hospitalized at the Chelyabinsk Regional Center for Oncology and Nuclear Medicine since 2016 to 2022. The mean age of the patients was 33.0 ± 11.21 years. In 60 % (n = 6) progression of grade 3 ependymoma was diagnosed, in 40 % (n = 4) relapse of grade 2 ependymoma was noted. All patients were female. The mean time to recurrence was 29.6 months (from 11 to 44 months). According to the method of relapse treatment, in 60 % (n = 6) of cases patients received monochemotherapy with temozolomide, 20 % (n = 2) of patients underwent stereotaxic radiotherapy on the CyberKnife device with a single focal dose (SOD) of 5.5 Gy in five fractions, before summing up the total focal dose (SOD) of 27.5 Gy, two patients underwent repeated external beam radiation therapy in the traditional mode of fractionation with SOD 40 Gy. The median overall survival (OS) for all patients was 48 months. Indicators of 1-year OR were 100 %, 2-year – 83.3 %, 3-year – 50 %. The median progression-free survival was 20 months. In the neurological status after the completion of the special treatment, a decrease in motor deficit and one aphatic disorder was noted.
About the Authors
M. M. Sarycheva
South Ural State Medical University; Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Russian Federation
Russian Federation
Sarycheva Marina M., PhD Med, assistant at Dept of Oncology, Radiation Diagnostics and Radiation Therapy; radiotherapist of Radiotherapy Dept. No. 1
Chelyabinsk
A. V. Vazhenin
South Ural State Medical University
Russian Federation
Russian Federation
Vazhenin Andrey V., DM Sci (habil.), professor, academician of RAS, head of Dept of Oncology, Radiation Diagnostics and Radiation Therapy
Chelyabinsk
E. Ya. Mozerova
South Ural State Medical University; Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Russian Federation
Russian Federation
Mozerova Ekaterina Ya., associate professor at Dept of Oncology, Radiation Diagnostics and Radiation Therapy; head of Radiotherapy Dept No. 1
Chelyabinsk
References
1. Pajtler K, Witt H, Sill M, Jones D, Hovestadt V, Kratochwil F, et al. Molecular classification of ependymal tumors across All CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015; 27 (5): 28–43.
2. Kresbach C, Neyazi S, Schüller U. Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond. Brain Pathol 2022. DOI: 10.1111/bpa.13068.
3. Yang D, Holsten T, Börnigen D, Frank S, Mawrin C, Glatzel M, et al. Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology. Brain Pathol. 2021; 31 (1): 33–44.
4. Rudà R, Bruno F, Pellerino A, Soffietti R. Ependymoma: Evaluation and Management Updates. Curr Oncol Rep. 2022. DOI: 10.1007/s11912–022–01260-w.
5. Brandes A, Cavallo G, Reni M, Tosoni A, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer. 2005; 104: 143–148.
6. Lorgis V, Varbedian O, Ghiringhelli F. Metronomic Cyclophosphamide with Cisplatin and Bevacizumab: A New Chemo-therapeutic Regimen for Refractory Anaplastic Ependymoma. Anticancer. Res. 2012; 32: 67–70.
7. Snyder M, Ampie L, Domenico J, Asthagiri A, et al. Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case. J. Clin. Neurosci. 2021; 135: 34–38.
8. Green R, Cloughesy T, Stupp R, DeAngelis L, Woyshner E, et al. Bevacizumab for recurrent ependymoma. Neurology. 2009; 73: 77–80.
9. Chamberlain M. C. Salvage chemotherapy for recurrent spinal cord ependymoma. Cancer. 2002; 95: 97–102.
10. Gilbert M, Yuan Y, Wu J, et al. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro-Oncology. 2020; 23: 68–77.
11. Gramatzki, D, Dorothee G, Felsberg J, et al. Chemotherapy for intracranial ependymoma in adults. BMC Cancer. 2016; 16: 1–12.
12. Rudà R, Bosa C, Magistrello M, et al. et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: A retrospective study. Neuro-Oncology. 2016; 18: 61–68.
13. Gupta T, Maitre M, Gupta P, et al. Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma J Neurooncol. 2020; 147 (2): 5–15. DOI: 10.1007/s11060–020–03434–7.
14. Kano H, Su Y, Wu H, Simonova G, et al. Stereotactic Radiosurgery for Intracranial Ependymomas: An International Multicenter Study. Neurosurgery. 2019 Jan 1; 84 (1): 27–34. DOI: 10.1093/neuros/nyy082.
15. Lin Y, Wu H, Yang H, et al. Repeated gamma knife radiosurgery enables longer tumor control in cases of highly-recurrent intracranial ependymoma. J Neurooncol. 2020; 148 (2): 63–72. DOI: 10.1007/s11060–020–03531–7.
16. Kano H, Su Y, Wu H, Simonova G, et al. Stereotactic Radiosurgery for Intracranial Ependymomas: An International Multicenter Study. Neurosurgery. 2019; 84 (1): 27–34. DOI: 10.1093/neuros/nyy082.
Review
For citations:
Sarycheva M.M., Vazhenin A.V., Mozerova E.Ya. Treatment of patients with progression of primary cerebral ependymomas in adults. Medical alphabet. 2023;(17):42-45. (In Russ.) https://doi.org/10.33667/2078-5631-2023-17-42-45
Views:
157
Email this article 